Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.

Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, Litvan I, Mata IF, Zabetian CP, Brundin P, Fernandez HH, Standaert DG, Kauffman MA, Schwarzschild MA, Sardi SP, Sherer T, Perry G, Leverenz JB.

Neurology. 2019 Feb 12;92(7):329-337. doi: 10.1212/WNL.0000000000006926.

PMID:
30745444
2.

End of life planning in parkinsonian diseases.

Gillard DM, Proudfoot JA, Simões RM, Litvan I.

Parkinsonism Relat Disord. 2019 Jan 30. pii: S1353-8020(19)30026-4. doi: 10.1016/j.parkreldis.2019.01.026. [Epub ahead of print]

PMID:
30718221
3.

Risk of Parkinson's disease dementia related to level I MDS PD-MCI.

Hoogland J, Boel JA, de Bie RMA, Schmand BA, Geskus RB, Dalrymple-Alford JC, Marras C, Adler CH, Weintraub D, Junque C, Pedersen KF, Mollenhauer B, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ; MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2019 Jan 17. doi: 10.1002/mds.27617. [Epub ahead of print]

PMID:
30653248
4.

The virtual reality of Parkinson's disease freezing of gait: A systematic review.

Bluett B, Bayram E, Litvan I.

Parkinsonism Relat Disord. 2018 Nov 15. pii: S1353-8020(18)30498-X. doi: 10.1016/j.parkreldis.2018.11.013. [Epub ahead of print] Review.

PMID:
30470656
5.

Clinical-Neuropathological Correlations of Alzheimer's Disease and Related Dementias in Latino Volunteers.

Soria JA, Huisa BN, Edland SD, Litvan I, Peavy GM, Salmon DP, Hansen LA, Galasko DR, Brewer JB, González HM, Rissman RA.

J Alzheimers Dis. 2018;66(4):1539-1548. doi: 10.3233/JAD-180789.

PMID:
30412501
6.

Altered Functional Interactions of Inhibition Regions in Cognitively Normal Parkinson's Disease.

Harrington DL, Shen Q, Theilmann RJ, Castillo GN, Litvan I, Filoteo JV, Huang M, Lee RR.

Front Aging Neurosci. 2018 Oct 23;10:331. doi: 10.3389/fnagi.2018.00331. eCollection 2018.

7.

Progress in the treatment of Parkinson-Plus syndromes.

Olfati N, Shoeibi A, Litvan I.

Parkinsonism Relat Disord. 2018 Oct 3. pii: S1353-8020(18)30432-2. doi: 10.1016/j.parkreldis.2018.10.006. [Epub ahead of print]

PMID:
30314846
8.

Prominent tongue and jaw tremor in a patient with probable Progressive Supranuclear Palsy.

Shoeibi A, Litvan I.

Mov Disord Clin Pract. 2018 Jan-Feb;5(1):99-100. doi: 10.1002/mdc3.12562. Epub 2017 Oct 23. No abstract available.

9.

Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine.

Moreno GM, Gandhi R, Lessig SL, Wright B, Litvan I, Nahab FB.

Neurology. 2018 Oct 23;91(17):797-799. doi: 10.1212/WNL.0000000000006396. Epub 2018 Sep 26. No abstract available.

10.

Does the Geriatric Depression Scale measure depression in Parkinson's disease?

Lopez FV, Split M, Filoteo JV, Litvan I, Moore RC, Pirogovsky-Turk E, Liu L, Lessig S, Schiehser DM.

Int J Geriatr Psychiatry. 2018 Dec;33(12):1662-1670. doi: 10.1002/gps.4970. Epub 2018 Sep 25.

PMID:
30251374
11.

Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests.

Hoogland J, van Wanrooij LL, Boel JA, Goldman JG, Stebbins GT, Dalrymple-Alford JC, Marras C, Adler CH, Junque C, Pedersen KF, Mollenhauer B, Zabetian CP, Eslinger PJ, Lewis SJG, Wu RM, Klein M, Rodriguez-Oroz MC, Cammisuli DM, Barone P, Biundo R, de Bie RMA, Schmand BA, Tröster AI, Burn DJ, Litvan I, Filoteo JV, Geurtsen GJ, Weintraub D; IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2018 Nov;33(11):1750-1759. doi: 10.1002/mds.110. Epub 2018 Sep 14.

PMID:
30216541
12.

Neuroimaging and neuropsychological assessment of freezing of gait in Parkinson's disease.

Bluett B, Banks S, Cordes D, Bayram E, Mishra V, Cummings J, Litvan I.

Alzheimers Dement (N Y). 2018 Jun 13;4:387-394. doi: 10.1016/j.trci.2018.04.010. eCollection 2018.

13.

Movement disorder society criteria for clinically established early Parkinson's disease.

Berg D, Adler CH, Bloem BR, Chan P, Gasser T, Goetz CG, Halliday G, Lang AE, Lewis S, Li Y, Liepelt-Scarfone I, Litvan I, Marek K, Maetzler C, Mi T, Obeso J, Oertel W, Olanow CW, Poewe W, Rios-Romenets S, Schäffer E, Seppi K, Heim B, Slow E, Stern M, Bledsoe IO, Deuschl G, Postuma RB.

Mov Disord. 2018 Oct;33(10):1643-1646. doi: 10.1002/mds.27431. Epub 2018 Aug 25.

PMID:
30145841
14.

Validation of the MDS clinical diagnostic criteria for Parkinson's disease.

Postuma RB, Poewe W, Litvan I, Lewis S, Lang AE, Halliday G, Goetz CG, Chan P, Slow E, Seppi K, Schaffer E, Rios-Romenets S, Mi T, Maetzler C, Li Y, Heim B, Bledsoe IO, Berg D.

Mov Disord. 2018 Oct;33(10):1601-1608. doi: 10.1002/mds.27362. Epub 2018 Aug 25.

PMID:
30145797
15.

Tauopathy-associated PERK alleles are functional hypomorphs that increase neuronal vulnerability to ER stress.

Yuan SH, Hiramatsu N, Liu Q, Sun XV, Lenh D, Chan P, Chiang K, Koo EH, Kao AW, Litvan I, Lin JH.

Hum Mol Genet. 2018 Nov 15;27(22):3951-3963. doi: 10.1093/hmg/ddy297.

16.

Cognition among individuals along a spectrum of increased risk for Parkinson's disease.

Chahine LM, Urbe L, Caspell-Garcia C, Aarsland D, Alcalay R, Barone P, Burn D, Espay AJ, Hamilton JL, Hawkins KA, Lasch S, Leverenz JB, Litvan I, Richard I, Siderowf A, Coffey CS, Simuni T, Weintraub D; Parkinson’s Progression Markers Initiative.

PLoS One. 2018 Aug 20;13(8):e0201964. doi: 10.1371/journal.pone.0201964. eCollection 2018.

17.

Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative.

Iddi S, Li D, Aisen PS, Rafii MS, Litvan I, Thompson WK, Donohue MC.

Neurodegener Dis. 2018;18(4):173-190. doi: 10.1159/000488780. Epub 2018 Aug 8.

18.

Traumatic Brain Injury and Firearm Use and Risk of Progressive Supranuclear Palsy Among Veterans.

Kelley KD, Checkoway H, Hall DA, Reich SG, Cunningham C, Litvan I.

Front Neurol. 2018 Jun 20;9:474. doi: 10.3389/fneur.2018.00474. eCollection 2018.

19.

Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype.

Koga S, Kouri N, Walton RL, Ebbert MTW, Josephs KA, Litvan I, Graff-Radford N, Ahlskog JE, Uitti RJ, van Gerpen JA, Boeve BF, Parks A, Ross OA, Dickson DW.

Acta Neuropathol. 2018 Jun 20. doi: 10.1007/s00401-018-1878-z. [Epub ahead of print]

PMID:
29926172
20.

Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy.

Shoeibi A, Olfati N, Litvan I.

Expert Opin Investig Drugs. 2018 Apr;27(4):349-361. doi: 10.1080/13543784.2018.1460356. Epub 2018 Apr 9. Review.

21.

Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment.

Litvan I, Kieburtz K, Tröster AI, Aarsland D.

Mov Disord. 2018 Apr;33(4):520-527. doi: 10.1002/mds.27345. Epub 2018 Mar 24. Review.

PMID:
29573469
22.

Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment.

Goldman JG, Holden SK, Litvan I, McKeith I, Stebbins GT, Taylor JP.

Mov Disord. 2018 Apr;33(4):503-510. doi: 10.1002/mds.27323. Epub 2018 Feb 28. Review.

PMID:
29488270
23.

Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study.

Park HK, Ilango S, Charriez CM, Checkoway H, Riley D, Standaert DG, Bordelon Y, Shprecher DR, Reich SG, Hall D, Kluger B, Marras C, Jankovic J, Dubinsky R, Litvan I; ENGENE-PSP Study.

Mov Disord. 2018 Mar;33(3):468-472. doi: 10.1002/mds.27336. Epub 2018 Feb 20.

PMID:
29460982
24.

At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease.

Weintraub D, Hamilton JL, Eberling J, Litvan I.

Mov Disord. 2018 Apr;33(4):501-502. doi: 10.1002/mds.27310. Epub 2018 Feb 8. No abstract available.

PMID:
29418018
25.

Anti-inflammatory drug use and progressive supranuclear palsy.

Marras C, Cunningham CR, Hou J, Proudfoot J, Standaert DG, Juncos J, Riley D, Reich SG, Hall D, Kluger B, Bordelon Y, Shprecher DR, Litvan I; for ENGENE-PSP.

Parkinsonism Relat Disord. 2018 Mar;48:89-92. doi: 10.1016/j.parkreldis.2017.11.346. Epub 2017 Dec 6.

PMID:
29307562
26.

Fall Prediction and Prevention Systems: Recent Trends, Challenges, and Future Research Directions.

Rajagopalan R, Litvan I, Jung TP.

Sensors (Basel). 2017 Nov 1;17(11). pii: E2509. doi: 10.3390/s17112509. Review.

27.

Genetic influences on cognition in progressive supranuclear palsy.

Gerstenecker A, Roberson ED, Schellenberg GD, Standaert DG, Shprecher DR, Kluger BM, Litvan I.

Mov Disord. 2017 Dec;32(12):1764-1771. doi: 10.1002/mds.27196. Epub 2017 Oct 27.

28.

18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study.

Schonhaut DR, McMillan CT, Spina S, Dickerson BC, Siderowf A, Devous MD Sr, Tsai R, Winer J, Russell DS, Litvan I, Roberson ED, Seeley WW, Grinberg LT, Kramer JH, Miller BL, Pressman P, Nasrallah I, Baker SL, Gomperts SN, Johnson KA, Grossman M, Jagust WJ, Boxer AL, Rabinovici GD.

Ann Neurol. 2017 Oct;82(4):622-634. doi: 10.1002/ana.25060.

29.

Aberrant Intrinsic Activity and Connectivity in Cognitively Normal Parkinson's Disease.

Harrington DL, Shen Q, Castillo GN, Filoteo JV, Litvan I, Takahashi C, French C.

Front Aging Neurosci. 2017 Jun 19;9:197. doi: 10.3389/fnagi.2017.00197. eCollection 2017.

30.

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU.

Lancet Neurol. 2017 Jul;16(7):552-563. doi: 10.1016/S1474-4422(17)30157-6. Epub 2017 Jun 13. Review.

31.

Mild cognitive impairment as a risk factor for Parkinson's disease dementia.

Hoogland J, Boel JA, de Bie RMA, Geskus RB, Schmand BA, Dalrymple-Alford JC, Marras C, Adler CH, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ; MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2017 Jul;32(7):1056-1065. doi: 10.1002/mds.27002. Epub 2017 Jun 12.

32.

Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease.

Caspell-Garcia C, Simuni T, Tosun-Turgut D, Wu IW, Zhang Y, Nalls M, Singleton A, Shaw LA, Kang JH, Trojanowski JQ, Siderowf A, Coffey C, Lasch S, Aarsland D, Burn D, Chahine LM, Espay AJ, Foster ED, Hawkins KA, Litvan I, Richard I, Weintraub D; Parkinson’s Progression Markers Initiative (PPMI).

PLoS One. 2017 May 17;12(5):e0175674. doi: 10.1371/journal.pone.0175674. eCollection 2017.

33.

Which ante mortem clinical features predict progressive supranuclear palsy pathology?

Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Giese A, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Whitwell JL, Antonini A, Bhatia KP, Bordelon Y, Corvol JC, Colosimo C, Dodel R, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici GD, Rowe JB, van Eimeren T, Wenning GK, Boxer A, Golbe LI, Litvan I, Stamelou M, Höglinger GU; Movement Disorder Society-Endorsed PSP Study Group.

Mov Disord. 2017 Jul;32(7):995-1005. doi: 10.1002/mds.27034. Epub 2017 May 13. Review.

34.

Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

Whitwell JL, Höglinger GU, Antonini A, Bordelon Y, Boxer AL, Colosimo C, van Eimeren T, Golbe LI, Kassubek J, Kurz C, Litvan I, Pantelyat A, Rabinovici G, Respondek G, Rominger A, Rowe JB, Stamelou M, Josephs KA; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2017 Jul;32(7):955-971. doi: 10.1002/mds.27038. Epub 2017 May 13. Review.

35.

Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2017 Jun;32(6):853-864. doi: 10.1002/mds.26987. Epub 2017 May 3.

36.

Psychometric Properties and Characteristics of the North-East Visual Hallucinations Interview in Parkinson's Disease.

Holiday KA, Pirogovsky-Turk E, Malcarne VL, Filoteo JV, Litvan I, Lessig SL, Song D, Schiehser DM.

Mov Disord Clin Pract. 2017 Sep-Oct;4(5):717-723. doi: 10.1002/mdc3.12479. Epub 2017 Mar 16.

37.

The Role of Stress as a Risk Factor for Progressive Supranuclear Palsy.

Kelley KD, Peavy G, Edland S, Rogers W, Riley DE, Bordelon Y, Standaert D, Reich SG, Litvan I.

J Parkinsons Dis. 2017;7(2):377-383. doi: 10.3233/JPD-160945.

38.

Levodopa-Responsive Parkinsonism Associated with Giant Virchow-Robin Spaces: A Case Report.

Shoeibi A, Litvan I.

Mov Disord Clin Pract. 2017 Mar 27;4(4):619-622. doi: 10.1002/mdc3.12484. eCollection 2017 Jul-Aug. No abstract available.

39.

Understanding falls in progressive supranuclear palsy.

Bluett B, Litvan I, Cheng S, Juncos J, Riley DE, Standaert DG, Reich SG, Hall DA, Kluger B, Shprecher D, Marras C, Jankovic J; ENGENE PSP study.

Parkinsonism Relat Disord. 2017 Feb;35:75-81. doi: 10.1016/j.parkreldis.2016.12.009. Epub 2016 Dec 15.

PMID:
28007518
40.

Neuropsychiatric Predictors of Cognitive Decline in Parkinson Disease: A Longitudinal Study.

Pirogovsky-Turk E, Moore RC, Filoteo JV, Litvan I, Song DD, Lessig SL, Schiehser DM.

Am J Geriatr Psychiatry. 2017 Mar;25(3):279-289. doi: 10.1016/j.jagp.2016.10.004. Epub 2016 Oct 12.

PMID:
27838315
41.

Progression of brain atrophy in PSP and CBS over 6 months and 1 year.

Dutt S, Binney RJ, Heuer HW, Luong P, Attygalle S, Bhatt P, Marx GA, Elofson J, Tartaglia MC, Litvan I, McGinnis SM, Dickerson BC, Kornak J, Waltzman D, Voltarelli L, Schuff N, Rabinovici GD, Kramer JH, Jack CR Jr, Miller BL, Rosen HJ, Boxer AL; AL-108-231 investigators.

Neurology. 2016 Nov 8;87(19):2016-2025. Epub 2016 Oct 14.

42.

Abolishing the 1-year rule: How much evidence will be enough?

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G.

Mov Disord. 2016 Nov;31(11):1623-1627. doi: 10.1002/mds.26796. Epub 2016 Sep 26. No abstract available.

PMID:
27666574
43.

Environmental Exposures and Parkinson's Disease.

Nandipati S, Litvan I.

Int J Environ Res Public Health. 2016 Sep 3;13(9). pii: E881. doi: 10.3390/ijerph13090881. Review.

44.

Progression of Microstructural Degeneration in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Longitudinal Diffusion Tensor Imaging Study.

Zhang Y, Walter R, Ng P, Luong PN, Dutt S, Heuer H, Rojas-Rodriguez JC, Tsai R, Litvan I, Dickerson BC, Tartaglia MC, Rabinovici G, Miller BL, Rosen HJ, Schuff N, Boxer AL.

PLoS One. 2016 Jun 16;11(6):e0157218. doi: 10.1371/journal.pone.0157218. eCollection 2016.

45.

The new definition and diagnostic criteria of Parkinson's disease.

Postuma RB, Berg D, Adler CH, Bloem BR, Chan P, Deuschl G, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Oertel W, Olanow CW, Poewe W, Stern M.

Lancet Neurol. 2016 May;15(6):546-8. doi: 10.1016/S1474-4422(16)00116-2. Epub 2016 Apr 11. No abstract available.

PMID:
27302120
46.

Cognitive functioning in individuals with Parkinson's disease and traumatic brain injury: A longitudinal study.

Schiehser DM, Filoteo JV, Litvan I, Pirogovsky-Turk E, Lessig SL, Song DS.

Parkinsonism Relat Disord. 2016 Sep;30:58-61. doi: 10.1016/j.parkreldis.2016.05.024. Epub 2016 May 24.

PMID:
27260791
47.

Technology in Parkinson's disease: Challenges and opportunities.

Espay AJ, Bonato P, Nahab FB, Maetzler W, Dean JM, Klucken J, Eskofier BM, Merola A, Horak F, Lang AE, Reilmann R, Giuffrida J, Nieuwboer A, Horne M, Little MA, Litvan I, Simuni T, Dorsey ER, Burack MA, Kubota K, Kamondi A, Godinho C, Daneault JF, Mitsi G, Krinke L, Hausdorff JM, Bloem BR, Papapetropoulos S; Movement Disorders Society Task Force on Technology.

Mov Disord. 2016 Sep;31(9):1272-82. doi: 10.1002/mds.26642. Epub 2016 Apr 29. Review.

48.

α-synuclein genetic variability: A biomarker for dementia in Parkinson disease.

Guella I, Evans DM, Szu-Tu C, Nosova E, Bortnick SF; SNCA Cognition Study Group, Goldman JG, Dalrymple-Alford JC, Geurtsen GJ, Litvan I, Ross OA, Middleton LT, Parkkinen L, Farrer MJ.

Ann Neurol. 2016 Jun;79(6):991-9. doi: 10.1002/ana.24664. Epub 2016 May 5.

49.

Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease.

Besser LM, Litvan I, Monsell SE, Mock C, Weintraub S, Zhou XH, Kukull W.

Parkinsonism Relat Disord. 2016 Jun;27:54-60. doi: 10.1016/j.parkreldis.2016.04.007. Epub 2016 Apr 9.

50.

Relationship between uric acid levels and progressive supranuclear palsy.

Brody DM, Litvan I, Warner S, Riley DE, Hall DA, Kluger BM, Shprecher DR, Cunningham CR.

Mov Disord. 2016 May;31(5):663-7. doi: 10.1002/mds.26535. Epub 2016 Feb 18.

Supplemental Content

Loading ...
Support Center